Sanofi : EC Oks Enjaymo For Treatment Of Hemolytic Anemia In Adult With Cold Agglutinin Disease
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Sanofi – Aventis Groupe said that the European Commission has granted marketing authorization for Enjaymo (sutimlimab) for the treatment of hemolytic anemia in adult patients with cold agglutinin disease, a rare, serious, and chronic autoimmune hemolytic anemia, where
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1632178785-2bbf98c928b749329959617a646e8bf8.jpg "How WhatsApp Makes Money")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1132012708-0d3f8f4b04c14405aa72e54940ab6a0e-3064dc565912458a94297c60b3d609e7.jpg "Is a Career in Investment Banking Worth It?")
:max_bytes(150000):strip_icc():format(jpeg)/KraftCadburyHostileTakeover-56143341d0004032a1cdb65ec3c2859b.jpg "What Are Some Top Examples of Hostile Takeovers?")
